89 results about "Protein s antigen" patented technology

The invention relates to screen for antigen epitope polypeptide, and building up of immunology detection method and the manufacturing and application for reagent for clinical diagnosis, especially for alpha-cyst albumen antigen epitope polypeptide.

The invention discloses an indirect ELISA method and kit for detecting serum 3-type duck hepatitis virus a antibody and belongs to the technical field of serum antibody detection. The indirect ELISA method includes that serum 3-type duck hepatitis virus VP1 protein is utilized as an envelope antigen with the peridium quantity as 0.1-1mug per hole, HRP-mice anti-duck IgY is utilized as the HRP with the use concentration as 0.2-2mug/mL, and the coloration time is 10 minutes. The kit comprises a VP1 protein antigen envelope board, the HRP-mice anti-duck IgY, sample diluent, a scrubbing solution, TMB solutions A and B and a stop solution. The method and the kit can be used for detecting the serum 3-type duck hepatitis virus a antibody in duck serum and duck egg yolk, and the serum does not have cross reaction with positive serum of other viruses. Compared with a traditional neutral reaction detection method, the method has the advantage of being convenient and accurate.

The invention relates beta-fordin antigen epitope polypeptide screening for gaining amino acid sequence corresponded with the optimum beta-fordin polypeptide. The beta-fordin antigent epitope polypeptide includes the following two that one is formed by the amino acid sequence showed in SEQ ID NO.1; another is derived from the above amino acid sequence by replacing, missing or adding one or many amino acid with antigen epitope function. It can used to specially test beta-fordin polypeptide IgG antibody for Sjogren syndrome patient. The invention also supplies the beta-fordin polypeptide IgG antibody immunology method, and its application used as antigen in Sjogren syndrome medicine preparation.

This invention relates to one functional central neutral damage dialogue test protein chip and its process method, which comprises the following steps: using protein chip to fix multiple central neutral system damage generation development key function abnormal protein factor antigen and its array; the said protein antigen and its array abnormal protein factors act as key property protein factors in the neutral system for inflammation and activation reaction and cell ion balance adjust and signal transmission.

The invention discloses an antituberculous CTL (Cytotoxic T Lymphocyte) epitope peptide with a drug-resistant related efflux protein source for tuberculosis. The antituberculous CTL epitope peptide is nonapeptide, wherein the amino acid sequence of the nonapeptide is P9: ALGML IAGL. Predicative analysis is carried out on HLA-A*0210 restrictive CTL epitope of drug-resistant related protein antigen for tuberculosis by adopting immune-informatics means and SYFPEITH1, BIMAS and NetCTL1.2 databases according to the primary structure of the antigen, so that the epitope peptide is obtained by screening; and the identified nonapeptide has not been reported in any document. An in-virto ELISPOT (Enzyme-Linked Immunospot Assay) is adopted to identify the epitope peptide; and the identification result provides a theoretical basis for developing tuberculosis vaccine based on drug-resistant related protein antigen and provides more information for designing multi-epitope peptide vaccine for tuberculosi based on the mixed T cell epitope.

The invention discloses a COVID-19 rapid diagnosis kit. The COVID-19 rapid diagnosis kit comprises COVID-19 spike protein antigen colloidal gold. The invention also discloses a preparation method of the COVID-19 rapid diagnosis kit. The preparation method comprises the following steps: expressing and purifying COVID-19 spike protein; and preparing the COVID-19 spike protein antigen colloidal gold.The kit is simple to operate, can quickly diagnose whether a patient is infected with COVID-19 or not, and is beneficial to effective control of epidemic situations.

The invention belongs to the field of biological products, and relates to a composite vaccine for Alzheimer's disease prevention and treatment, wherein the composite vaccine is prepared by mixing a nucleic acid vaccine encoding Abeta42 and a protein gene engineering vaccine. Experiment results show that: Abeta42 protein antigen expressed through prokaryotic expression and pVAX-Abeta42 plasmid are adopted to co-immunize, such that the Alzheimer's disease protein vaccine in the prior art is improved, high level anti-Abeta antibody IgG can be produced, inhibition on T cell response can be induced, and the inhibition can be maintained for a fairly long time. In addition, the antibody generated through co-immunizing and for Abeta can be combined with Abeta protein fibers and nature Abeta protein precipitate in APP/PS1 Alzheimer's disease transgene incidence mice brain so as to provide Abeta precipitate removing capacity; and the vaccine is a potential, effective, and side effect-free vaccine, and can be used for Alzheimer's disease prevention and treatment.

The present invention relates to one kind of bivalent livestock type-A and type-O foot and mouth disease DNA vaccine. It is prepared through connecting serially the coding regions of the VP1 protein antigen determinants of both type-A and type-O foot and mouth disease virus strains, and the connection with DNA segment capable of raising the immunogenicity. The preparation process includes connecting enzyme incised segment with eukaryotic expression carrier and transforming competent colibacillus cell; PCR identification to obtain positive cloning; culturing, collecting thallus, cracking cell and centrifuging; and other steps. The bivalent livestock type-A and type-O foot and mouth disease DNA vaccine is used to immunize livestock to generate antibody resisting both type-A and type-O foot and mouth disease viruses. It has no pathogenetic effect and can induce the livestock body to generate comprehensive immune response and express modified natural antigen.

The invention relates to a specific Thr1861 site phosphorylated antigen peptide aiming at a human NOTCH1 NICD protein, an antibody, application of the antigen peptide and the antibody, and a preparation method of the antibody. The antibody is shown as SEQ ID NO:1 through an active amino acid sequence, Thr amino acid is phosphorylated and prepared as an antigen peptide immunized animal. When the antibody is prepared, antiserum is purified by utilizing an affinity purification-affinity separation technology. The preparation method has the advantages of being short in preparation period, high in antibody potency, good in recovery rate, and the like; the obtained antibody has high specificity and high affinity; the phosphorylated antibody is helpful to reveal an action mechanism of phosphorylation modification of the NOTCH1 NICD protein in the occurrence and development of tumors and other diseases, and has wide clinical application prospect in accepts of tumor diagnosis, treatment, prognosis judgment and the like.

The invention discloses a preparation method of a novel genetically recombinant pure protein antigen and relates to the technical field of protection of hemagglutinin viruses and development of detection reagents. The preparation process comprises the following steps: I, gene recombinant expression of a hemagglutinin H7 antigen; II, preparation of the hemagglutinin H7 antigen; III, application of the hemagglutinin pure protein to animals/human bodies; and IV, application of the high purity hemagglutinin H7 antigen to detecting hemagglutinin H7-containing viruses. The novel genetically recombinant pure protein antigen has the characteristics of high purity and good antigenicity, and does not exist in form of granules and not only does not contain any genetic materials such as RNA (Ribonucleic Acid), but also does not contain other protein impurities. The novel genetically recombinant pure protein antigen can be used for preparing a high specific antibody for H7N9. Because of the protein characteristic of the H7 antigen, the chromatographic method can be used for purifying a single antigen, and the purity of SEC-HPCL (Size Exclusion Chromatography-High Performance Liquid Chromatography) is higher than 90%. The high purity H7 antigen and the highly specific H7N9 antibody can be used for developing diagnostic reagents for diagnosing H7N9 avian influenza.

The invention provides a method for preparing a pET-28a-SUMO-coagulation factor II protein antigen and a polyclonal antibody thereof. According to the method, a grass carp coagulation factor II gene sequence is synthesized by using a grass carp coagulation factor II specific primer through a PCR amplification technology, then cloned into a pET-28a-SUMO expression vector, then delivered into E. coli Rosetta for expression and then purified to obtain the pET-28a-SUMO-coagulation factor II protein antigen, the antigen is used for repeated immunization of laboratory-scale Japanese white rabbits, blood sampling is carried out, antiserum is collected, pET-28a-SUMO-coagulation factor II protein is used as the antigen for affinity purification, and the concentrated grass crap coagulation factor IIpolyclonal antibody is obtained. The method can obtain the concentrated grass carp coagulation factor II polyclonal antibody meeting the requirements of subsequent experiments, thereby providing an important experimental reagent for the subsequent detection of the expression of the grass carp coagulation factor II.

The invention discloses a modified seasonal flu-RSV (Respiratory Syncytial Virus) combined vaccine and a preparation method thereof. The modified seasonal flu-RSV combined vaccine is prepared from a flu protein antigen, an RSV protein antigen and a nanoparticle carrier, wherein the surface of the nanoparticle carrier is hydroxylated; the flu protein antigen and the RSV protein antigen react with hydroxyl groups on the surface of the nanoparticle carrier and are connected to the surfaces to nanoparticles. According to the modified seasonal flu-RSV combined vaccine disclosed by the invention, the nanoparticles are used as a novel protein carrier, antigen protein is efficiently and stably connected, and the nanoparticles having a flu antigen and an RSV antigen at the same time are successfully constructed; an experiment on mice verifies that a good systemic immune response can be caused, the nanoparticles are used as the carrier and can be repeatedly synthesized, the stability is high, not only can digestion of all kinds of enzymes in a body be resisted, but also the modified seasonal flu-RSV combined vaccine has many advantages of tolerating high pressure, sterilizing and the like. By adopting the nanoparticles as the novel protein carrier, the method is simple, the operation is simple and convenient, various protein and polysaccharide antigens can be connected, too much modification is not needed, and a good application prospect is obtained.

The present invention provides a lateral flow test device for detecting a coronavirus antibody by immunoassay; the test device includes three lateral flow test strips; a first test strip is directed to the antibody detection of a N full-length protein and/or an S full-length protein antigens/antigen; and a second test strip is directed to the antibody detection of an S-RBD-site protein antigen, and both of the first strip and the second strip are combined to detect novel coronavirus IgG and IgM antibodies, which can practically reduce the possibility of missing detection and wrong detection; further, a third test strip is directed to the detection of a neutralizing antibody at an S-RBD site to rapidly detect the neutralizing antibody having protection effect, thus further helping the prevention of missing detection and helping patients to perform self-detection and judge the situations of recovery, or vaccine immunity.

The invention provides a method for generating a novel induction antibody, which comprises a step of preparing a eukaryotic expression vector expressing fusion antigen protein. The fusion protein consists of four parts of sequences: (1) a signal peptide sequence from a human IgE heavy-chain coded sequence; (2) an antigen protein sequence; (3) an auxiliary sequence from a mycobacterium tuberculosis cytochrome C oxidase subunit II, wherein the sequence can amplify the antibody response of the rat and mice against the antigen protein; and (4) a polypeptide sequence MFSRMTSLIMGN that can be combined with the mice FcrR II (APCTS for short), wherein the sequence can specifically guide the protein antigen to the mice antigen-presenting cell (APC) so as to improve the antigen presenting efficiency. The plasmid expressing the fusion antigen protein is directly injected into the mice muscle or skin, and the mice cells can take in DNA (deoxyribonucleic acid) and the efficiently-expressed fusion antigen protein; and then the animal is stimulated to generate a high-affinity antibody against the antigen protein. The generated antibody after being purified can be applied to the scientific research and clinical diagnosis or treatment; and the antibody secretion cell can be used for preparing a specific monoclonal antibody by use of the hybridoma technology.

The invention belongs to the field of protein engineering, and particularly relates to duck adenovirus type I Penton protein as well as a preparation method and application thereof. The inventor, by analysis, finds that the Penton protein has the advantages of hydrophilicity, no transmembrane structural domain, no signal peptide prediction and the like, and full-length expression is selected. A Penton target fragment is obtained through artificial synthesis after sequence optimization, and the expression mode of the protein is cell-free protein expression. Compared with truncated expression ofantigen dominant epitopes of traditional Penton protein, the artificially synthesized and expressed Penton recombinant protein is high in accuracy, the neutrality of the protein is guaranteed, the trouble of high mutation rate is avoided, and the application to the development of an antibody detection technology is better facilitated. In addition, an expression system has unique advantages of saving time and improving the total yield of soluble full-length protein. Furthermore, the expression system is low in cost, large in expression quantity and high in Western Blot detection reactogenicity.

The invention discloses a bovine respiratory syncytial cell virus antigen protein. Compared with SEQ 048055.1, an amino acid sequence of the bovine respiratory syncytial cell virus antigen protein is provided with at least two loci substituted by cysteines, the substitutive cysteines are connected through a disulfide bond, improvements such as internal disulfide bond, hole filling and single stranded connection are also performed on the basis, and meanwhile a preparation method of the antigen protein is provided. The antigen protein applies the technique and theory of protein crystallography, the structural change of the protein in virus infection and pathopoiesis process is determined, and then genetic engineering modification is conducted on the key virus protein according to a structural change result, so that the protein becomes a protein antigen only infecting without pathopoiesis and causing efficient reaction of animal body antibodies. The antigen protein can effectively prevent and treat bovine respiratory syncytial cell virus infection, an ideal viral vaccine can be developed on the basis, loss brought by virus inflection can be effectively controlled and prevented, and the antigen protein has great economic significance and social significance.